Bradley Corr, MD

Professional Titles

• LeBert-Suess Family Endowed Professorship in Ovarian Cancer Research
• Director of Clinical Research for Gynecologic Oncology

Publications

• Corr BR, Carrubba A, Sheeder J, Cheng G, Guntupalli SR. Histopathology Discrepancy of Preoperative Endometrial Sampling and Final Specimen: How Does This Influence Selective Lymph Node Dissection?. Int J Gynecol Cancer. 2016 Nov 17. [Epub ahead of print] PubMed PMID: 27870710
• Corr BR, Breed C, Sheeder J, Weisdack S, Behbakht K. Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?. Gynecol Oncol Rep. 2016 Jun 16;17:65-8. PubMed PMID: 27617286
• Carrubba AR, Corr BR, Sheeder J, Guntupalli SR. Evaluation of Preoperative Chest Imaging in Low-Risk Endometrial Cancer Patients. Int J Gynecol Cancer. 2016 Feb;26(2):348-53. PubMed PMID: 26807565
• Moroney MR, Post MD, Berning AA, Sheeder J, Corr BR. An Evaluation of Frozen Section and Lymph Node Dissection Results for Mucinous Ovarian Tumors. Int J Gynecol Cancer. 2018 Jan;28(1):92-98. PubMed PMID: 29194190
• Corr BR, Carrubba A, Sheeder J, Cheng G, Guntupalli SR. Histopathology Discrepancy of Preoperative Endometrial Sampling and Final Specimen: How Does This Influence Selective Lymph Node Dissection?. Int J Gynecol Cancer. 2017 Feb;27(2):297-301. PubMed PMID: 27870710
• Amini A, Robin TP, Stumpf PK, Rusthoven C, Schefter TE, Shinde A, Chen YJ, Glaser SM, Corr BR, Fisher CM. Rising Rates of Upfront Surgery in Early Locally Advanced Cervical Cancer: What Factors Predict for This Treatment Paradigm?. Int J Gynecol Cancer. 2018 Oct;28(8):1560-1568. PubMed PMID: 30247249
• Ramzan AA, Behbakht K, Corr BR, Sheeder J, Guntupalli SR. Minority Race Predicts Treatment by Non-gynecologic Oncologists in Women with Gynecologic Cancer. Ann Surg Oncol. 2018 Nov;25(12):3685-3691. PubMed PMID: 30105439
• Amini A, Robin TP, Rusthoven CG, Schefter TE, Akhavan D, Chen YJ, Glaser SM, Corr BR, Ashing KT, Fisher CM. Disparities Predict for Higher Rates of Cut-through Hysterectomies in Locally Advanced Cervical Cancer. Am J Clin Oncol. 2019 Jan;42(1):21-26. PubMed PMID: 29889138
• Moroney MR, Post MD, Berning AA, Sheeder J, Corr BR. An Evaluation of Frozen Section and Lymph Node Dissection Results for Mucinous Ovarian Tumors. Int J Gynecol Cancer. 2018 Jan;28(1):92-98. PubMed PMID: 29194190
• Davis SL, Lam ET , Corr BR, O'Bryant CL, Glode, Adler AN, Pitts TM, Tentler JJ, Capasso A, Dailey K, Serkova NJ, Weekes CD, Gustafson DL, Lieu CH, Messersmith WA, Leong S, Eckhardt SG, Diamond JR. A phase Ib study of the combination of MLN0128 (dual TORC1/2 inhibitor) and MLN8237 (Aurora A inhibitor, alisertib) in patients with advanced solid tumors. Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A083.
• Serkova NJ, Singel DJ, Lam ET, Leong S, Corr BR, Messersmith WA, Diamond JR. Tumor response assessment using diffusion weighted imaging (DWI) in patients with liver metastases treated with Aurora A and TORC1/2 inhibitors. Journal of Clinical Oncology 2018 36:15_suppl, e14573-e14573. ASCO 2018.
• A E Wahner Hendrickson, B Costello, A Jewell, V Kennedy, G Fleming, B Corr, S E Taylor, J Lea, J Reid, E Swisher, D Satele, J Allred, J Lensing, S P Ivy, C Erlichman, A A Adjei, S Kaufmann; 1001TiP A phase II clinical trial of veliparib and topotecan in patients with platinum resistant ovarian cancer, Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy285.208, https://doi.org/10.1093/annonc/mdy285.208
• S Fu, B Corr, E Hamilton, R A Burger, R Wenham, R W Naumann, R Stagg, K N Moore; 951P A phase Ib study of navicixizumab & weekly paclitaxel in heavily pre-treated platinum resistant ovarian, primary peritoneal or fallopian tube cancer, Annals of Oncology, Volume 29, Issue suppl_8, 1 October 2018, mdy285.159, https://doi.org/10.1093/annonc/mdy285.159
• Moroney MR, Wheeler LJ, Corr BR. Clinical presentation of brain metastases from endometrial carcinoma: A case series. Gynecol Oncol Rep. 2019 May;28:79-83. PubMed PMID: 30963086
• Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, Fisher C, Lefkowits C, Guntupalli SR, Behbakht K, Corr BR. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019 Jun;153(3):517-520. PubMed PMID: 30910249
• Amini A, Robin TP, Rusthoven CG, Schefter TE, Akhavan D, Chen YJ, Glaser SM, Corr BR, Ashing KT, Fisher CM. Disparities Predict for Higher Rates of Cut-through Hysterectomies in Locally Advanced Cervical Cancer. Am J Clin Oncol. 2019 Jan;42(1):21-26. PubMed PMID: 29889138
• Moroney M, Hill B, Sheeder J, Diamond JR, Avella-Howell M, Corr BR, Lefkowits, C. Integration of specialty palliative care in a phase I ovarian cancer population. Journ Clin Oncol 37, no 31. November 01, 2019. 75.
• Corr BR, Moroney M, Sheeder J, Sawyer B, Eckhardt G, Behbakht K, Diamond JR. Survival and clinical outcomes of ovarian cancer patients enrolled in phase I clinical trials. Journ Clinc Oncol 37, no 15. May 20, 2019. 5559.
• Friedman CF, Snyder Charen A, Zhou Q, Carducci MA, Buckley De Meritens A, Corr BR, Fu S, Hollmann TJ, Iasonos A, Konner JA, Konstantinopoulos PA, Modesitt SC, Sharon E, Aghajanian C, Zamarin D. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer. 2020 Oct;8(2). PubMed PMID: 33004542
• Corr BR, Moroney M, Sheeder J, Eckhardt SG, Sawyer B, Behbakht K, Diamond JR. Survival and clinical outcomes of patients with ovarian cancer who were treated on phase 1 clinical trials. Cancer. 2020 Oct 1;126(19):4289-4293. PubMed PMID: 32697381
• Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, Cheng G, Ramzan AA, Wheeler LJ, Corr BR, Lefkowits C, Sheeder J, Matsuo K, Flink D. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e207410. PubMed PMID: 32589230
• Jimeno A, Opyrchal M, Diamond JR, Fountzilas C, Corr BR, Bezi I, Wang H, Kwan R, Zhi J, Cutler D, Boland PM. A pahse I study of the oral administration of irinotecan in combination with the potent P-glycoportein (P-gp) inhibitor HM30181A. Journ Clinc Oncol 37, no. 1. May 20, 2019. 3032.
• McMellen A, Woodruff ER, Corr BR, Bitler BG, Moroney MR. Wnt Signaling in Gynecologic Malignancies. Int J Mol Sci. 2020 Jun 16;21(12). PubMed PMID: 32560059
• Friedman CF, Snyder A, Sharon E, Buckley De Meritens A, Cantrell L, Corr BR, Fu S, Konner J, Konstantinopoulos P, Soldan K, Iasonos A, Aghajanian C, Zamarin D. A Phase 2 Study of Atezolizumab in Combination with Bevacizumab in Patients with Recurrent, Persistent or Metastatic Cervical Cancer. Society of Gynecologic Oncology Annual Meeting: Honolulu, Hawaii. March 15th-19th, 2019.
• Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 Sep 1;26(17):4633-4642. PubMed PMID: 32414750
• Haag J, Hardie L, Berning A, Fishbein L, Corr BR. Case report of a paraganglioma arising from a mature cystic teratoma of the ovary. Gynecol Oncol Rep. 2020 May;32:100537. PubMed PMID: 32042879
• Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 Aug;60(8):511-523. PubMed PMID: 34038589
• Victorson D, Doninger G, Victorson S, Victorson G, Hall L, Maletich C, Corr BR, Scortino K, Burns Z, Allen L, Rosa I, Quirk K, Adegbemi A, Strokoff J, Zuidema K, Sajdak K, Mckibben T, Roberts A, McDade TW, Boes A, McAlinden K, Arredondo K, Sauer C, Smith K, Salsman JM. Psychosocial and Biological Outcomes of Immersive, Mindfulness-Based Treks in Nature for Groups of Young Adults and Caregivers Affected by Cancer: Results from a Single Arm Program Evaluation from 2016-2021. Int J Environ Res Public Health. 2021 Nov 30;18(23). PubMed PMID: 34886348
• Moroney MR, Woodruff E, Qamar L, Bradford AP, Wolsky R, Bitler BG, Corr BR. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer. Mol Carcinog. 2021 Aug;60(8):511-523. PubMed PMID: 34038589
• Targeting Wnt/beta-catenin signaling in CTNNB1-mutant endometrial cancer, Gynecologic Oncology, Volume 162, Supplement 1, 2021
• Clinicopathologic evaluation of CTNNB1 gene mutations in high-intermediate risk endometrial cancer, Gynecologic Oncology, Volume 162, Supplement 1, 2021
• Hilton J, Cristea M, Postel-Vinay S, Baldini C, Voskoboynik M, Edenfield W, Shapiro GI, Cheng ML, Vuky J, Corr B, Das S, Apfel A, Xu K, Kozicki M, Ünsal-Kaçmaz K, Hammell A, Wang G, Ravindran P, Kollia G, Esposito O, Coker S, Diamond JR. BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial. Cancers (Basel). 2022 Aug 23;14(17). PubMed PMID: 36077617
• Boland PM, Fountzilas C, Fakih M, Opyrchal M, Diamond JR, Corr B, Ma WW, Redman M, Chan WK, Wang H, Kramer D, Kwan R, Cutler D, Zhi J, Jimeno A. A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies. Cancer Chemother Pharmacol. 2022 Aug;90(2):175-187. PubMed PMID: 35904620
• Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results. Jodi A. Kagihara, Bradley Corr, Jose Maria Pacheco, S. Lindsey Davis, Christopher Hanyoung Lieu, Sunnie S. Kim, Antonio Jimeno, Amy M. Heim, John A. DeMattei, Gilad Gordon, Todd A. Triplett, S. Gail Eckhardt, James D. Winkler, Anthony D. Piscopio, and Jennifer Robinson Diamond Journal of Clinical Oncology 2021 39:15_suppl, 3075-3075
• Fu S, Corr BR, Culm-Merdek K, Mockbee C, Youssoufian H, Stagg R, Naumann RW, Wenham RM, Rosengarten RD, Benjamin L, Hamilton EP, Moore KN. Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2022 Aug 10;40(23):2568-2577. PubMed PMID: 35439029
• Haag JG, Wolsky RJ, Moroney MR, Sheren J, Sheeder J, Bitler BG, Corr BR. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma. Int J Gynecol Pathol. 2023 Jan 1;42(1):43-53. PubMed PMID: 35283443
• Corr B, Cosgrove C, Spinosa D, Guntupalli S. Endometrial cancer: molecular classification and future treatments. BMJ Medicine. 2022 Oct 1;1(1).
• E.P Hamilton, S Goel, R Aren, C Chu, DL Richardson, B Corr, V John, F Janku, J Hays, M Michenzie, W Reichman, H Achour, ML Cherman, R Ruiz-Soto, C Mathews. 728P A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer. Annals of Oncology, Volume 32, S731 - S732.
• Fu, Siqing, Bradley R. Corr, Kerry Culm-Merdek, Colleen Mockbee, Hagop Youssoufian, Robert Stagg, R. Wendel Naumann et al. "Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients with Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer." Journal of Clinical Oncology (2022): JCO-21.
• Corr, Bradley, Marisa Moroney, Elizabeth Woodruff, Rebecca Wolsky, and Benjamin Bitler. "Endometrial cancer antitumor response with combination Wnt inhibition and taxanes (270)." Gynecologic Oncology 166 (2022): S144.
• Secord, Angeles Alvarez, Bhavana Pothuri, Floor Backes, Premal Thaker, Paola Gehrig, Rebecca Previs, Lindsay Borden et al. "Genomic alterations, molecularly targeted therapy and race: Real world data from the Endometrial Cancer Molecularly Targeted Therapy Consortium (LBA 8)." Gynecologic Oncology 166 (2022): S52-S53.
• Davis, S. Lindsey, Alexis Diane Leal, Wells A. Messersmith, Christopher Hanyoung Lieu, Elaine T. Lam, Bradley Corr, Cindy L. O'Bryant, Natalie Julie Serkova, Todd Pitts, and Jennifer Robinson Diamond. "A phase Ib study of the combination of alisertib (Aurora A kinase inhibitor) and MLN0128 (dual TORC1/2 Inhibitor) in patients with advanced solid tumors, final expansion cohort data." (2022): 3112-3112.
• Lheureux, Stephanie, Husam Alqaisi, David E. Cohn, Jing-Yi Chern, Linda R. Duska, Andrea Jewell, Bradley Corr et al. "A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial# 10150." (2022): 5514-5514.
• Xu, Yanfei, Allison Saiz, Bj Rimel, Bradley Corr, Angeles Alvarez Secord, Leslie Horn Clark, Masha Kocherginsky et al. "Surgical window-of-opportunity study of megestrol acetate compared with megestrol acetate and metformin for endometrial intraepithelial neoplasia." (2022): TPS5601-TPS5601.
• Riggs, M.J., Lin, N., Miller, R.W., Piecoro, D.W., Schneider, B.P., Chon, H.S., Carpten, J.D., Churchman, M.L., Corr, B., Washington, C. and Dood, R., 2022. DACH1 mutation frequency in endometrial cancer is associated with high tumor mutation burden in a nationwide cohort.
• Eskander, Ramez, Lisa Abaid, Bradley Corr, James Mason, Fabio Cappuccini, Richard Friedman, Rockelle Robles, Katrina Lopez, Gabriel Nistor, and Robert Dillman. "562 Tumor collection and establishment of tumor-initiating cell cultures to serve as the antigen source for AV-OVA-1 dendritic cell vaccines for patients with newly diagnosed advanced ovarian cancer." (2022).
• Pino, Devon, Lynelle Smith, Kurtis Davies, Amber Berning, Miriam Post, Bradley Corr, Saketh Guntupalli, Christine Fisher, Dara Aisner, and Rebecca Wolsky. "Implementation of Endometrial Cancer TCGA Classification Using ProMisE: Experience at a Tertiary Care Center." In LABORATORY INVESTIGATION, vol. 102, no. SUPPL 1, pp. 814-815. CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND: SPRINGERNATURE, 2022.
• Hendrickson, Andrea E. Wahner, Nathan Foster, Bradley R. Corr, Linda Duska, Merry J. Markham, Kristina Butler, Eugenia Girda et al. "2022-RA-464-ESGO A phase i dose escalation and expansion cohort trial of carboplatin and gemcitabine with the ATR inhibitor berzosertib in first or second recurrence platinum sensitive epithelial ovarian, peritoneal, and fallopian tube cancer." (2022).
• Gutierrez, M., Friedman, C.F., Long, G.V., Ascierto, P.A., Melero, I., Richards, D., Bastos, B.R., Garcia, V.M., Uemura, M., Conkling, P. and Corr, B.R., 2022. 740P Anti-cytotoxic T-lymphocyte antigen-4 (CTLA 4) probody BMS-986249±nivolumab (NIVO) in patients (pts) with advanced cancers: Updated phase I results. Annals of Oncology, 33, p.S882.
• Mason, James, Lisa Abaid, Bradley Corr, Ramez Eskander, Fabio Cappuccini, Richard Friedman, Rockelle Robles, Katrina Lopez, Gabriel Nistor, and Robert Dillman. "565 Leukapheresis to obtain monocytes to produce dendritic cells for manufacturing AV-OVA-1 personal vaccines in a randomized phase II trial in patients with newly diagnosed advanced ovarian cancer." (2022).
• Sottnik JL, Shackleford MT, Robinson SK, Villagomez FR, Bahnassy S, Oesterreich S, Hu J, Madak-Erdogan Z, Riggins RB, Corr BR, Cook LS, Treviño LS, Bitler BG, Sikora MJ. WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers. Cancer Res Commun. 2023 Dec 19. [Epub ahead of print] PubMed PMID: 38112643
• Davies KD, Smith LP, Guimaraes-Young A, Corr BR, Fisher CM, Guntupalli SR, Berning AA, Post MD, Pino D, Aisner DL, Wolsky RJ. Prospective Clinical Prognostication of Endometrial Carcinomas Based on Next-Generation Sequencing and Immunohistochemistry-Real-World Implementation and Results at a Tertiary Care Center. Int J Gynecol Pathol. 2023 Oct 4. [Epub ahead of print] PubMed PMID: 37922951
• Whelan K, Dillon M, Strickland KC, Pothuri B, Bae-Jump V, Borden LE, Thaker PH, Haight P, Arend RC, Ko E, Jackson AL, Corr BR, Ayoola-Adeola M, Wright JD, Podwika S, Smitherman C, Thomas S, Lightfoot M, Newton M, Washington C, Mullen M, Cosgrove C, Harsono AAH, Powell K, Herzog TJ, Salani R, Alvarez Secord A. TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes. Gynecol Oncol. 2023 Nov;178:44-53. PubMed PMID: 37748270
• Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S. A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. Int J Gynecol Cancer. 2023 Aug 7;33(8):1208-1214. PubMed PMID: 37380217
• Corr BR, Moroney MR, Woodruff E, Watson ZL, Jordan KR, Danhorn T, Bailey C, Wolsky RJ, Bitler BG. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer. bioRxiv. 2023 Apr 6. PubMed PMID: 37066339
• Haag JG, Wolsky RJ, Moroney MR, Sheren J, Sheeder J, Bitler BG, Corr BR. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma. Int J Gynecol Pathol. 2023 Jan 1;42(1):43-53. PubMed PMID: 35283443
• Corr, B., Thomas, S., Haight, P., Stock, E., Floyd, J., Borden, L., Tunnage, I., Secord, A.A., Arend, R., Jackson, A. and Wright, J., 2023. PR023/# 503 Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability
• Sottnik JL, Shackleford MT, Robinson SK, Villagomez FR, Bahnassy S, Oesterreich S, Hu J, Madak-Erdogan Z, Riggins RB, Corr BR, Cook LS. WNT4 regulates cellular metabolism via intracellular activity at the mitochondria in breast and gynecologic cancers. Cancer Research Communications. 2023 Dec 19. (AACR 2023)
• Diermayr V, Tan D, Ngoi NY, Ng M, Messersmith W, Corr B, Sun W, Srirangam V, Cometa J, Blanchard S, Nellore R. EP311/# 691 Efficacy of the porcupine inhibitor ETC-1922159 (ETC-159) plus pembrolizumab in microsatellite stable (MSS) or proficient mismatch repair (PMMR) platinum resistant ovarian carcinomas (PROC). (IGCS 2023)
• Santin A, Corr B, Spira AI, Willmott L, Butrynski JE, Tse KY, Patel J, Mekan S, Wu T, Dumbrava EE. TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC). DOI: 10.1200/JCO.2023.41.16_suppl.5610 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 5610-5610. (ASCO 2023)
• Corr B, Abaid LN, Mason JR, Eskander RN, Cappuccini F, Lopez KL, Keirstead HS, Nistor GI, Dillman RO. Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer. DOI: 10.1200/JCO.2023.41.16_suppl.5560 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) 5560-5560. (ASCO 2023)
• Corr B, Haggerty AF, Taylor SE, Gysler S, Morgan MA, Behbakht K, Lefkowits C, Alldredge J, Brubaker L, Hopp S, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer. DOI: 10.1200/JCO.2023.41.16_suppl.TPS5626 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) TPS5626-TPS5626. (ASCO 2023)
• Greenwood A, Castro M, Corr B, Alldredge J, Guntupalli S, Behbakht K, Bitler B, Walsh C. Closing the testing gap: Trends in germline and somatic genetic testing in ovarian cancer (2165). Gynecologic Oncology. 2023 (SGO 2023)
• Lee S, Secord AA, Hade E, Smitherman C, Bisht N, Borden L, Jackson A, Backes F, Thaker P, Arend R, Wright, Corr B, Ko E, Konecny G, Podwika S, Bae-Jump V, Pothuri B. J. Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium (029). Gynecologic Oncology. 2023 Sep 1;176:S22.
• Riggs M, Lin N, Hill K, Mao G, Knicely B, Piecoro D, Schneider BP, Chon H, Carpten JD, Churchman M, Corr B. Increased Incidence of DACH1 Mutation in Appalachian Women with Uterine Cancer and Altered Chemotherapy Sensitivity.

Practice Locations

• University of Colorado Hospital

• University of Colorado Cancer Center

Specialty Information

• Gynecologic Oncology